Kezar Life Sciences, Inc. (NASDAQ:KZR) Short Interest Up 5.6% in March

Kezar Life Sciences, Inc. (NASDAQ:KZR) saw a large growth in short interest during the month of March. As of March 31st, there was short interest totalling 3,570,000 shares, a growth of 5.6% from the March 15th total of 3,380,000 shares. Based on an average trading volume of 717,500 shares, the short-interest ratio is presently 5.0 days.

Analysts Set New Price Targets

Separately, HC Wainwright reiterated a “buy” rating and issued a $20.00 price target on shares of Kezar Life Sciences in a research note on Friday, March 15th.

Kezar Life Sciences Stock Down 6.2 %

Shares of NASDAQ:KZR opened at $0.81 on Tuesday. The firm has a market cap of $58.93 million, a P/E ratio of -0.57 and a beta of 0.47. The company has a quick ratio of 11.66, a current ratio of 11.66 and a debt-to-equity ratio of 0.05. Kezar Life Sciences has a 12-month low of $0.67 and a 12-month high of $3.13. The business has a fifty day simple moving average of $0.90 and a 200 day simple moving average of $0.89.

Kezar Life Sciences (NASDAQ:KZR) last announced its earnings results on Thursday, March 14th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.39) by $0.04. Analysts predict that Kezar Life Sciences will post -1.26 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of KZR. RVW Wealth LLC bought a new position in Kezar Life Sciences during the 3rd quarter worth $28,000. Amundi bought a new position in Kezar Life Sciences during the 4th quarter worth $32,000. SG Americas Securities LLC bought a new position in shares of Kezar Life Sciences in the 3rd quarter worth about $39,000. Acadian Asset Management LLC bought a new position in shares of Kezar Life Sciences in the 1st quarter worth about $45,000. Finally, Two Sigma Securities LLC bought a new position in shares of Kezar Life Sciences in the 1st quarter worth about $45,000. 67.90% of the stock is owned by institutional investors.

About Kezar Life Sciences

Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis.